Rein Therapeutics (NASDAQ:RNTX) received a Buy rating from Rodman & Renshaw, with a newly established price target of $8.00. The firm began its coverage of the biotech company, highlighting its focus ...
Nvidia ( NVDA -2.62%) stock posted another year of explosive gains in 2024. The company's share price closed out the year's trading up 171.2%, according to data from S&P Global Market Intelligence.
Shares of the next-generation financial services company were popular following a settlement deal with a regulator, not to mention several glowing analyst notes on its business. According to data ...